The TREAT EARLIER trial presented at ACR Convergence 2024 showed that a 1-year course of methotrexate can prevent anti-citrullinated protein autoantibody-negative rheumatoid arthritis in high-risk patients with clinically suspect arthralgia. The study included ACPA-negative patients with CSA and subclinical joint inflammation who were at an increased risk for RA. Results showed a reduction in RA development in the ACPA-negative, increased-risk group compared to placebo. This suggests that methotrexate may be an effective preventive strategy for ACPA-negative RA in high-risk patients with CSA. The study found no difference in the ACPA-positive group.
Source link
Early methotrexate course may prevent rheumatoid arthritis in some high-risk patients
